BI
VRTX icon

Binnacle Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Binnacle Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$17.2K Sell
44
-38
-46% -$15.9K 0.01% 309
2025
Q2 		$36.5K Sell
82
-24
-23% -$11.1K 0.02% 166
2025
Q1 		$51.4K Buy
+106
New +$49.4K 0.04% 130

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Binnacle Investments's VRTX Position: Q3 2025 in Review

Binnacle Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 46% in Q3 2025, selling an estimated $15.9K and leaving 44 shares worth $17.2K. The position accounts for 0.01% of the portfolio, ranked #309.

Binnacle Investments first reported a position in VRTX in Q1 2025 and has held it in 3 quarters since. The position peaked at $51.4K in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Binnacle Investments held 44 shares of Vertex Pharmaceuticals worth $17.2K as of Q3 2025.
  • Binnacle Investments sold 38 Vertex Pharmaceuticals shares in Q3 2025, an estimated $15.9K.
  • Vertex Pharmaceuticals made up 0.01% of Binnacle Investments's portfolio in Q3 2025, its #309 holding.
  • Binnacle Investments first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Binnacle Investments's Vertex Pharmaceuticals position peaked at $51.4K in Q1 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.